Journal of Equine Veterinary Science
Volume 30, Issue 5 , Pages 237-243 , May 2010

Field Trial Validation of the Efficacy and Acceptability of Firocoxib, a Highly Selective Cox-2 Inhibitor, in a Group of 96 Lame Horses

  • Marc Koene, DVM

      Affiliations

    • Tierklinik Lüsche, Bakum-Lüsche, Germany
    • Corresponding Author InformationReprint requests: Marc Koene, Tierklinik Lüsche, D-49456 Bakum-Lüsche, Germany.
    • ,
  • Xavier Goupil, DVM

      Affiliations

    • Ecole Nationale d'Equitation, Saumur Cedex, France
    • ,
  • Clemens Kampmann, DVM

      Affiliations

    • Tierklinik Wahlstedt, Wiesenweg, Wahlstedt, Germany
    • ,
  • Peter D. Hanson, DVM, PhD

      Affiliations

    • Merial Limited, Duluth, GA
    • ,
  • Davida Denton, MPH

      Affiliations

    • Merial Limited, Duluth, GA
    • ,
  • Matthias G. Pollmeier, DVM

      Affiliations

    • Merial S.A.S., Saint Vulbas, France

References 

  1. Stashak TS. Examination of lameness. In:  Stashak TS editors. Adams' lameness in horses. 5th ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2002;p. 113–183
  2. Casey J. Healthy Horses Workshop, held in conjunction with the American Association of Equine Practitioners 52nd annual convention; December 2, 2006; San Antonio, TX.
  3. Jeffcott LB, Rossdale PD, Freestone JE. An assessment of wastage in thoroughbred racing from conception to 4 years of age. Equine Vet J. 1982;14:185–198
  4. Morris EA, Seeherman HJ. Clinical evaluation of poor performance in the racehorse: the results of 275 evaluations. Equine Vet J. 1991;23:169–174
  5. Fitzpatrick FA. Cyclooxygenase enzymes: regulation and function. Curr Pharm Des. 2004;10:577–588
  6. Wilson JE, Chandrasekharan NV, Westover KD, Eager KB, Simmons DL. Determination of expression of cyclooxygenase-1 and -2 isozymes in canine tissues and their differential sensitivity to nonsteroidal anti-inflammatory drugs. Am J Vet Res. 2004;65:810–818
  7. Vane JR, Botting RM. The history of anti-inflammatory drugs and their mechanism of action. In: Bazan NG, Botting J, Vane JR, eds. Proceedings of the New targets in inflammation. Inhibitors of Cox-2 on adhesion molecules; April 15-16, 1996; New Orleans, LA.
  8. Wallace JL, Reuter BK, Mcknight W, Bak A. Selective inhibitors of cyclooxygenase-2: are they really effective, selective, and GI-safe?. J Clin Gastroenterol. 1998;27(Suppl 1):S28–S34
  9. Zimmermann KC, Sabria M, Schrör K, Weber A-A. Constitutive cyclooxygenase-2 expression in healthy human and rabbit gastric mucosa. Mol Pharmacol. 1998;54:536–540
  10. Wolfe MM, Lichtenstein DR, Gurkirpal S. Gastrointestinal toxicity of nonsteroidal antiinflammtory drugs. N Engl J Med. 1999;340:1888–1899
  11. Gilroy DW, Colville-Nash PR. New insights into the role of COX-2 in inflammation. J Mol Med. 2000;78:121–129
  12. Macnaugthon WK, Cushing K. Role of constitutive Cox-2 in prostaglandin-dependent secretion in Mouse Colon in vitro. J Pharmacol Exp Ther. 2000;293:539–544
  13. Brzozowski T, Konturek PC, Konturek SJ, Sliwowski Z, Pajdo R, Drozdowicz D, et al. Classic NSAID and selective cyclooxygenase (COX)-1 and COX-2 inhibitors in healing of chronic gastric ulcers. Microsc Res Tech. 2001;53:343–353
  14. Khan KNM, Stanfield KM, Trajkovic D, Harris RK. Expression of cyclooxygenase-2 in canine renal cell carcinoma. Vet Pathol. 2001;38:116–119
  15. Einhorn TA. The role of cyclooxygenase-2 in bone repair. Arthritis Res Ther. 2002;5:5–7
  16. Warner TD, Mitchell JA. Cyclooxygenases: new forms, new inhibitors, and lessons from the clinic. FASEB J. 2004;18:790–804
  17. Brzozowska I, Targosz A, Sliwowski Z, Kwiecien S, Drozdowicz D, Pajdo R, et al. Healing of chronic gastric ulcers in diabetic rats treated with native aspirin, nitric oxide (NO)-derivative of aspirin and cyclooxygenase (COX)-2 inhibitor. J Physiol Pharmacol. 2004;55:773–790
  18. McCann ME, Andersen DR, Brideau C, Black WC, Zhang D-H, Hickey GJ. In vitro activity and in vivo efficacy of a novel Cox-2 inhibitor in the horse (abstract). J Vet Int Med. 2002;16:355
  19. Bergh MS, Budsberg SC. The coxib NSAIDs: potential clinical and pharmacologic importance in veterinary medicine. J Vet Intern Med. 2005;19:633–643
  20. Sackett DL, Straus SE, Richardson WS, Rosenberg W, Haynes RB. Evidence-based medicine: how to practice and teach EBM. London: Churchill Livingston; 2000;ISBN 0-443-06240-4
  21. Viitanen M, Bird J, Maisi P, Smith R, Tulamo RM, May S. Differences in the concentration of various synovial fluid constituents between the distal interphalangeal joint, the metacarpophalangeal joint and the navicular bursa in normal horses. Res Vet Sci. 2000;69:63–67
  22. Malone ED. Managing chronic arthritis. Vet Clin North Am Equine Pract. 2002;18:411–437
  23. Doucet MY, Bertone AL, Hendrickson D, Hughes F, MacAllister C, McClure S, et al. Comparison of efficacy and safety of paste formulations of firocoxib and phenylbutazone in horses with naturally occurring osteoarthritis. J Am Vet Med Assoc. 2008;232:91–97
  24. MacAllister CG, Morgan SJ, Borne AT, Pollet RA. Comparison of adverse effects of phenylbutazone, flunixin meglumine, and ketoprofen in horses. J Am Vet Med Assoc. 1993;202:71–77
  25. Monreal L, Sabate D, Segura D, Mayos I, Homedes J. Lower gastric ulcerogenic effect of suxibuzone compared to phenylbutazone when administered orally to horses. Res Vet Sci. 2004;76:45–149
  26. Meschter CL, Gilbert M, Krook L, Maylin G, Corradino R. The effects of phenylbutazone on the intestinal mucosa of the horse: a morphological, ultrastructural and biochemical study. Equine Vet J. 1990;22:255–263
  27. Ramirez S, Seahorn TL, Williams J. Renal medullary rim sign in 2 adult quarter horses. Can Vet J. 1998;39:647–649
  28. Goodrich LR, Furr MO, Robertson JL, Warnick LD. A toxicity study of eltenac, a nonsteroidal anti-inflammatory drug, in horses. J Vet Pharmacol Ther. 1998;21:24–33

PII: S0737-0806(10)00176-0

doi: 10.1016/j.jevs.2010.03.011

Journal of Equine Veterinary Science
Volume 30, Issue 5 , Pages 237-243 , May 2010

Article Tools

* Image Usage & Resolution